Shares rise after quarterly revenue includes license income
Shares of genetic medicine firm MeiraGTx MGTX.O rise 6% to $13.74
Company reports Q2 revenue of $321.43 million, including $204.6 million in license revenue. There was no license revenue a year earlier
License revenue relates to MeiraGTx's proprietary gene therapy delivery platform, which enables precise, small-volume brain infusions and has been licensed to Reogen Limited for the development of neurology-focused therapies, including Parkinson's disease
Including session's move, MGTX shares are up 73% year to date
MGTX•
